Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

Chitogel inks heads of agreement with big pharma

Chitogel inks heads of agreement with big pharma for US launch

By Rebecca Howard

Nov. 8 (BusinessDesk) - New Zealand medical science company Chitogel has signed a heads of agreement with a US-based pharmaceutical multinational after getting greenlit by the US Food and Drug Administration for its wound-healing gel.

"We just signed the deal yesterday. They are the largest or second largest in the US in the ears, nose and throat space," chief executive Phil Royal told BusinessDesk. He declined to name the company but said it would be Chitogel's distributor for the ENT gel in the US. Chitogel is aiming to capture 20 percent to 30 percent of the US market by 2020 and Royal said he was confident that was possible. Now the company has regulatory approval from the FDA, he expects the first commercial shipments to begin in the middle of next year.

Royal said the company currently has the capacity at its new manufacturing plant in Lower Hutt's Gracefield Innovation Quarter to meet demand from the US but would then have to expand as it moves into other markets and other products.

The gel, which has been 12 years in the making, is used post-operatively in endoscopic sinus surgery, performed approximately 500,000 times each year in the US alone. The clear gel is a topical medical treatment that reduces bleeding, scarring and infection resulting from sinus operations, according to the company. Among other things, the dissolvable clear gel dressings replace the need for gauze bandages, improving the recovery.

"It's very effective material," said Lyall Hanton, a chemistry professor at Otago University and one of the developers of the project. While Chitogel does have some competition in the ENT space he is confident the gel offers a better outcome for patients.

Hanton said the company is submitting applications to secure FDA clearance for post-surgery use in spinal and abdominal surgeries, likely focusing on spinal use first. According to Royal, human testing just kicked off today in Adelaide for spinal use.

The company also has global patents in place and will look to get regulatory approval in several markets outside the US. "Every market is slightly different in terms of how you approach it and the cost of approaching it," said Hanton.

(BusinessDesk receives assistance from Callaghan Innovation to cover the commercialisation of innovation)

(BusinessDesk)

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Stats NZ: Consents For New Homes At All-Time High

A record 41,028 new homes have been consented in the year ended March 2021, Stats NZ said today. The previous record for the annual number of new homes consented was 40,025 in the year ended February 1974. “Within 10 years the number of new homes ... More>>

Stats NZ: Unemployment Declines As Underutilisation Rises

The seasonally adjusted unemployment rate decreased to 4.7 percent in the March 2021 quarter, continuing to fall from its recent peak of 5.2 percent in the September 2020 quarter but remaining high compared with recent years, Stats NZ said today. ... More>>

ALSO:

Digitl: The Story Behind Vodafone’s FibreX Court Ruling

Vodafone’s FibreX service was in the news this week. What is the story behind the Fair Trading Act court case? More>>

Reserve Bank: Concerned About New Zealand's Rising House Prices

New Zealand house prices have risen significantly in the past 12 months. This has raised concerns at the Reserve Bank of New Zealand – Te Putea Matua about the risk this poses to financial stability. Central banks responded swiftly to the global ... More>>

Westpac: Announces Strong Financial Result

Westpac New Zealand (Westpac NZ) [i] says a strong half-year financial result has been driven by better than expected economic conditions. Chief Executive David McLean said while the global COVID-19 pandemic was far from over, the financial effect on ... More>>

MYOB: SME Confidence In Economic Performance Still Cautious

New insights from the annual MYOB Business Monitor have shown the SME sector is still cautious about the potential for further economic recovery, with two-in-five (41%) expecting the New Zealand economy to decline this year. The latest research ... More>>